行情

NBIX

NBIX

神经分泌生物科学
NASDAQ

实时行情|Nasdaq Last Sale

85.09
-1.46
-1.69%
盘后: 85.09 0 0.00% 16:59 04/01 EDT
开盘
83.72
昨收
86.55
最高
86.87
最低
83.66
成交量
103.21万
成交额
--
52周最高
119.65
52周最低
71.85
市值
78.53亿
市盈率(TTM)
258.00
分时
5日
1月
3月
1年
5年

分析师评级

23位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测NBIX价格均价为120.50,最高价位147.00,最低价为105.00。

EPS

NBIX 新闻

更多
  • Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates
  • Benzinga · 1天前
  • XBI: Biotech ETF Expected To Outperform During And After The Coronavirus Pandemic
  • Seeking Alpha - Article · 1天前
  • FDA Decisions on 5 Drugs Expected in 2nd Quarter
  • GuruFocus.com · 2天前
  • A Trio of Stocks Growing Capex Fast
  • GuruFocus.com · 5天前

所属板块

生物技术和医学研究
-4.52%
制药与医学研究
-2.91%

热门股票

代码
价格
涨跌幅

NBIX 简况

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.
展开

微牛提供Neurocrine Biosciences, Inc.(NASDAQ-NBIX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的NBIX股票新闻,以帮助您做出投资决策。